This publication is intended as an educational resource for New Zealand healthcare professionals. It reviews risk factors, incidence and burden associated with meningococcal group B disease in children aged <5 years, focusing on the New Zealand setting, as well as evidence for the use of MenB (Bexsero; 4CMenB), the only vaccine available in this country for invasive group B meningococcal disease.
This publication has been commissioned and funded by GSK. The content is based on published studies and the author’s opinions and may not reflect the views of GSK. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. All trademarks mentioned in this review are the property of their respective owners.
Please login below to download this issue (PDF)